Yes: It Bureaucratizes, Politicizes Research

When techniques for sequencing segments of DNA became available, it seemed self-evident that the most valuable material to analyze was the regions that could be associated with a function or a disease. More than 95 percent of the human genome did not seem interesting to explore in detail because it does not code for the kinds of functions that we can recognize, and so it is temporarily called "junk." A few years ago, however, it was proposed that systematic sequencing of the entire human genome

Written byBernard Davis
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

This human genome program had an unusual origin. It was not initiated by a committee of molecular geneticists dealing with a pressing need, or by the major biomedical funding agency, the National Institutes of Health. Instead, it was advanced by an administrator in the Department of Energy, convinced that with the powerful tools of molecular biology it was now time to introduce centrally administered "big science" into biomedical research.

The idea quick-ly developed strong political appeal. Sequencing the entire human genome was as definite and as highly visible as putting a man on the moon; it promised large benefits for human health and for our understanding of human biology; and it was claimed to be more efficient and cheaper than reaching the goal eventually by piecemeal sequencing. The NIH was initially not supportive, but when the program proved to be inevitable, it became the logical major partner. The HGP has ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies